Debt reduction from asset monetization
Expected: Q4 FY26MEDIUM confidence
₹275.52 crores from land/building disposal to improve D/E ratio by Q4 FY26
“Q3 FY26 exceptional gain of ₹275.52 crores from property sale”
Unichem Laboratories Ltd: Stock Analysis & Fundamentals
Updated this weekUnichem Laboratories Ltd (Pharma - Others) — fundamental analysis, earnings data, and key metrics. PE: 19.0. ROE: 5.6%. This stock is not currently in the Nifty 500 momentum outperformers list.
Re-Rating Catalysts
1. Debt reduction from asset monetization
Q4 FY26MEDIUM
2. USFDA audit resolution
Q1 FY27LOW
3. Margin recovery to 12-14% OPM
Q4 FY26MEDIUM
Value Trap Risks
1. Working capital trap
HIGH2. Structural industry decline
MEDIUMKey Numbers
Current Price
₹284
Market Cap
2.0K Cr
Valuation
N/AIs Unichem Laboratories Ltd a Turnaround Opportunity?
Deep value thesis based on recent earnings • Updated Feb 22, 2026
Asset monetization and governance improvements could catalyze margin recovery and debt reduction if core business stabilizes.
Verdict
WAIT_FOR_CONFIRMATION
What Could Re-Rate Unichem Laboratories Ltd?
Re-rating catalysts over the next 2-4 quarters • Updated Feb 22, 2026
USFDA audit resolution
Expected: Q1 FY27LOW confidence
Expected within 2 quarters to restore export market confidence and pricing power
“USFDA audit mentioned in industry reports as ongoing concern”
Margin recovery to 12-14% OPM
Expected: Q4 FY26MEDIUM confidence
Through cost optimization initiatives already underway
“Sequential OPM improvement from 4.27% in Q1 to 8.59% in Q3 FY26”
What Are the Value Trap Risks for Unichem Laboratories Ltd?
Risks that could prevent re-rating or deepen the value trap
Working capital trap
HIGHContinued inventory build-up or receivables collection issues
Impact: -500 bps margin impact
Management view: Company is addressing through working capital optimization initiatives
Monitor: CFO to Revenue ratio
Structural industry decline
MEDIUMFurther price erosion in key markets
Impact: -300 bps margin impact
Management view: Company focusing on niche products and export markets
Monitor: Export revenue growth rate
What Is Unichem Laboratories Ltd's Management Guidance?
Forward-looking targets from management for FY27
Management Tone: CAUTIOUS
Key Milestones
• USFDA audit resolution
• Debt reduction completion
• Margin recovery to 12-14%
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Frequently Asked Questions: Unichem Laboratories Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Unichem Laboratories Ltd's latest quarterly results?
Unichem Laboratories Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +355.2%
- Revenue Growth YoY: -2.3%
- Operating Margin: 9.0%
What is Unichem Laboratories Ltd's current PE ratio?
Unichem Laboratories Ltd's current PE ratio is 19.0x.
- Current PE: 19.0x
- Market Cap: 2.0K Cr
What is Unichem Laboratories Ltd's price-to-book ratio?
Unichem Laboratories Ltd's price-to-book ratio is 0.8x.
- Price-to-Book (P/B): 0.8x
- Book Value per Share: ₹346
- Current Price: ₹284
Is Unichem Laboratories Ltd a fundamentally strong company?
Unichem Laboratories Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 6.0%
Is Unichem Laboratories Ltd debt free?
Unichem Laboratories Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹502 Cr
What is Unichem Laboratories Ltd's return on equity (ROE) and ROCE?
Unichem Laboratories Ltd's return ratios over recent years
- FY2023: ROCE -5.0%
- FY2024: ROCE 0.0%
- FY2025: ROCE 6.0%
Is Unichem Laboratories Ltd's cash flow positive?
Unichem Laboratories Ltd's operating cash flow is negative (FY2025).
- Cash from Operations (CFO): ₹-7 Cr
- Free Cash Flow (FCF): ₹-249 Cr
- CFO/PAT Ratio: -5% (weak cash conversion)
What is Unichem Laboratories Ltd's dividend yield?
Unichem Laboratories Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹284
Who holds Unichem Laboratories Ltd shares — promoters, FII, DII?
Unichem Laboratories Ltd's shareholding pattern (Dec 2025)
- Promoters: 70.2%
- FII (Foreign): 1.0%
- DII (Domestic): 10.7%
- Public: 18.1%
Is promoter holding increasing or decreasing in Unichem Laboratories Ltd?
Unichem Laboratories Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 70.2% (Dec 2025)
- Previous Quarter: 70.2% (Sep 2025)
- Change: 0.00% (stable)
Is Unichem Laboratories Ltd a new momentum entry or an established outperformer?
Unichem Laboratories Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
What are the growth catalysts for Unichem Laboratories Ltd?
Unichem Laboratories Ltd has 3 key growth catalysts identified from recent earnings analysis
- Debt reduction from asset monetization
- USFDA audit resolution
- Margin recovery to 12-14% OPM
What are the key risks in Unichem Laboratories Ltd?
Unichem Laboratories Ltd has 2 key risks worth monitoring
- Working capital trap
- Structural industry decline
What is Unichem Laboratories Ltd's management guidance for growth?
Unichem Laboratories Ltd's management has provided the following forward guidance for FY27
- Management tone: cautious
- Milestone: USFDA audit resolution
- Milestone: Debt reduction completion
Is Unichem Laboratories Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Unichem Laboratories Ltd may be worth studying
- Currently showing mixed signals — monitor for clearer trend confirmation
What is the investment thesis for Unichem Laboratories Ltd?
Unichem Laboratories Ltd investment thesis summary:
Research Signals (Bull Case)
- Growth catalyst: Debt reduction from asset monetization
Risk Factors (Bear Case)
- Key risk: Working capital trap
What is the future outlook for Unichem Laboratories Ltd?
Unichem Laboratories Ltd's forward outlook based on current data signals
- Key Catalyst: Debt reduction from asset monetization
- Key Risk: Working capital trap
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.